These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26323665)

  • 1. Urinary and genital infections in patients with diabetes: How to diagnose and how to treat.
    Njomnang Soh P; Vidal F; Huyghe E; Gourdy P; Halimi JM; Bouhanick B
    Diabetes Metab; 2016 Feb; 42(1):16-24. PubMed ID: 26323665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes.
    Arakaki RF
    Postgrad Med; 2016 May; 128(4):409-17. PubMed ID: 26982554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors.
    Dave CV; Schneeweiss S; Patorno E
    Diabetes Obes Metab; 2019 Feb; 21(2):434-438. PubMed ID: 30207042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes.
    Lega IC; Bronskill SE; Campitelli MA; Guan J; Stall NM; Lam K; McCarthy LM; Gruneir A; Rochon PA
    Diabetes Obes Metab; 2019 Nov; 21(11):2394-2404. PubMed ID: 31264755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria].
    Sturov NV; Popov SV; Mamporia NK; Mager AA
    Ter Arkh; 2020 Dec; 92(11):106-109. PubMed ID: 33720614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors.
    Dardi I; Kouvatsos T; Jabbour SA
    Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes.
    Nichols GA; Brodovicz KG; Kimes TM; Déruaz-Luyet A; Bartels DB
    J Diabetes Complications; 2017 Nov; 31(11):1587-1591. PubMed ID: 28888425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials.
    Dailey G
    J Diabetes; 2015 Jul; 7(4):448-61. PubMed ID: 25676662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.
    Boyle LD; Wilding JP
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):375-91. PubMed ID: 23968378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin: Improving diabetes by making urine sweet.
    Vouyiouklis M
    Cleve Clin J Med; 2013 Nov; 80(11):683-7. PubMed ID: 24186885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
    Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
    J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus.
    Barnett AH
    Postgrad Med; 2013 Sep; 125(5):92-100. PubMed ID: 24113667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic bacteriuria and symptomatic urinary tract infections (UTI) in patients with diabetes mellitus in Tikur Anbessa Specialized University Hospital, Addis Ababa, Ethiopia.
    Yeshitela B; Gebre-Selassie S; Feleke Y
    Ethiop Med J; 2012 Jul; 50(3):239-49. PubMed ID: 23409407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes and balanoposthitis.
    Kalra S; Chawla A
    J Pak Med Assoc; 2016 Aug; 66(8):1039-41. PubMed ID: 27524547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database.
    Hirji I; Andersson SW; Guo Z; Hammar N; Gomez-Caminero A
    J Diabetes Complications; 2012; 26(6):501-5. PubMed ID: 22840886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.